U.S. markets closed
  • S&P 500

    4,283.74
    +9.70 (+0.23%)
     
  • Dow 30

    33,999.04
    +18.72 (+0.06%)
     
  • Nasdaq

    12,965.34
    +27.22 (+0.21%)
     
  • Russell 2000

    2,000.73
    +13.41 (+0.68%)
     
  • Crude Oil

    90.55
    +2.44 (+2.77%)
     
  • Gold

    1,773.40
    -3.30 (-0.19%)
     
  • Silver

    19.49
    -0.24 (-1.22%)
     
  • EUR/USD

    1.0093
    -0.0087 (-0.86%)
     
  • 10-Yr Bond

    2.8800
    -0.0130 (-0.45%)
     
  • GBP/USD

    1.1936
    -0.0116 (-0.96%)
     
  • USD/JPY

    135.8750
    +0.7850 (+0.58%)
     
  • BTC-USD

    23,403.15
    +89.21 (+0.38%)
     
  • CMC Crypto 200

    558.63
    +0.90 (+0.16%)
     
  • FTSE 100

    7,541.85
    +26.10 (+0.35%)
     
  • Nikkei 225

    28,942.14
    -280.63 (-0.96%)
     

Heron Therapeutics to Report Second Quarter 2022 Financial Results on Tuesday, August 9, 2022

  • Oops!
    Something went wrong.
    Please try again later.
·2 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

SAN DIEGO, Aug. 2, 2022 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing and commercializing therapeutic innovations that improve medical care, today announced that the company will host a conference call and live webcast on Tuesday, August 9, 2022 at 8:30 a.m. ET to report second quarter 2022 financial results and discuss recent business highlights.

The conference call can be accessed by dialing (646) 307-1963 in the U.S. or (800) 715-9871 internationally.  Please provide the operator with the passcode 4215874 to join the conference call. The conference call will also be available via webcast under the Investor Relations section of Heron's website at www.herontx.com. An archive of the teleconference and webcast will also be made available on Heron's website for 60 days following the call.

About Heron Therapeutics, Inc.

Heron Therapeutics, Inc. is a commercial-stage biotechnology company focused on improving the lives of patients by developing and commercializing therapeutic innovations that improve medical care. Our advanced science, patented technologies, and innovative approach to drug discovery and development have allowed us to create and commercialize a portfolio of products that aim to advance the standard-of-care for acute care and oncology patients. For more information, visit www.herontx.com.

Forward-looking Statements

This news release contains "forward-looking statements" as defined by the Private Securities Litigation Reform Act of 1995. Heron cautions readers that forward-looking statements are based on management's expectations and assumptions as of the date of this news release and are subject to certain risks and uncertainties that could cause actual results to differ materially. These risks and uncertainties include, but are not limited to, risks and uncertainties identified in the Company's filings with the Securities and Exchange Commission. Forward-looking statements reflect our analysis only on their stated date, and Heron takes no obligation to update or revise these statements except as may be required by law.

Investor Relations and Media Contact:
David Szekeres
Executive Vice President, Chief Operating Officer
Heron Therapeutics, Inc.
dszekeres@herontx.com
858-251-4447

Cision
Cision

View original content:https://www.prnewswire.com/news-releases/heron-therapeutics-to-report-second-quarter-2022-financial-results-on-tuesday-august-9-2022-301598400.html

SOURCE Heron Therapeutics, Inc.